Literature DB >> 15491476

Frequency doubling perimetry screening mode compared to the full-threshold mode.

Remco Stoutenbeek1, Govert P Heeg, Nomdo M Jansonius.   

Abstract

The diagnostic performance of the frequency doubling perimetry (FDT) C20-1 screening mode was compared to that of the C20 full-threshold mode. For the number of defects p < 1% in the total deviation plot, both modes appeared to perform similarly in terms of sensitivity, specificity, and area under the receiver-operating characteristic (ROC) curve. Different cut-off points should be applied for both modes to obtain equal sensitivity and specificity values, and - related to that - for most subjects more defects were found in full-threshold mode than in screening mode. For the screening mode, we found a sensitivity of 0.91 and a specificity of 0.88 at a cut-off point of >0 defects, and an area under the ROC curve of 0.93.

Mesh:

Year:  2004        PMID: 15491476     DOI: 10.1111/j.1475-1313.2004.00223.x

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  4 in total

1.  Meta-analysis of the diagnostic efficiency of frequency-doubling technology for primary glaucoma.

Authors:  Ting Liu; Xiangge He
Journal:  Front Med China       Date:  2007-02

2.  Glaucoma screening during regular optician visits: can the population at risk of developing glaucoma be reached?

Authors:  R Stoutenbeek; N M Jansonius
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

3.  The association of office intraocular pressure fluctuation in ocular hypertension with frequency doubling technology perimetry abnormality.

Authors:  Volkan Dayanir; Sayime Aydin; Pinar Okyay
Journal:  Int Ophthalmol       Date:  2007-10-16       Impact factor: 2.031

4.  Genetic pre-screening for glaucoma in population-based epidemiology: protocol for a double-blind prospective screening study within Lifelines (EyeLife).

Authors:  Anna Neustaeter; Ilja Nolte; Harold Snieder; Nomdo M Jansonius
Journal:  BMC Ophthalmol       Date:  2021-01-07       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.